Phenytoin Toxicity Differential Diagnoses

1. Colombo E, Franceschetti S, Avanzini G, Mantegazza M. Phenytoin inhibits the persistent sodium current in neocortical neurons by modifying its inactivation properties. PLoS One. 2013. 8 (1):e55329. [QxMD MEDLINE Link]. [Full Text].

2. Craig S. Phenytoin poisoning. Neurocrit Care. 2005. 3(2):161-70. [QxMD MEDLINE Link].

3. McCluggage LK, Voils SA, Bullock MR. Phenytoin toxicity due to genetic polymorphism. Neurocrit Care. 2009. 10(2):222-4. [QxMD MEDLINE Link].

4. Dorado P, López-Torres E, Peñas-Lledó EM, Martínez-Antón J, Llerena A. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms. Pharmacogenomics J. 2012 May 29. [QxMD MEDLINE Link].

5. Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Rivers LJ, Feldman R, et al. 2021 Annual Report of the National Poison Data System(©) (NPDS) from America's Poison Centers: 39th Annual Report. Clin Toxicol (Phila). 2022 Dec. 60 (12):1381-1643. [QxMD MEDLINE Link]. [Full Text].

6. Rissardo JP, Caprara ALF. Phenytoin-associated movement disorder: A literature review. Tzu Chi Med J. 2022 Oct-Dec. 34 (4):409-417. [QxMD MEDLINE Link]. [Full Text].

7. Adams BD, Buckley NH, Kim JY, Tipps LB. Fosphenytoin may cause hemodynamically unstable bradydysrhythmias. J Emerg Med. 2006 Jan. 30(1):75-9. [QxMD MEDLINE Link].

8. Chokshi R, Openshaw J, Mehta NN, Mohler E 3rd. Purple glove syndrome following intravenous phenytoin administration. Vasc Med. 2007 Feb. 12(1):29-31. [QxMD MEDLINE Link].

9. Tobler A, Hösli R, Mühlebach S, Huber A. Free phenytoin assessment in patients: measured versus calculated blood serum levels. Int J Clin Pharm. 2016 Apr. 38 (2):303-9. [QxMD MEDLINE Link].

10. Kiang TK, Ensom MH. A Comprehensive Review on the Predictive Performance of the Sheiner-Tozer and Derivative Equations for the Correction of Phenytoin Concentrations. Ann Pharmacother. 2016 Apr. 50 (4):311-25. [QxMD MEDLINE Link].

11. Sen S, Ratnaraj N, Davies NA, Mookerjee RP, Cooper CE, Patsalos PN. Treatment of phenytoin toxicity by the molecular adsorbents recirculating system (MARS). Epilepsia. 2003 Feb. 44(2):265-7. [QxMD MEDLINE Link].

12. [Guideline] Benson BE, Hoppu K, Troutman WG, Bedry R, Erdman A, Höjer J, et al. Position paper update: gastric lavage for gastrointestinal decontamination. Clin Toxicol (Phila). 2013 Mar. 51 (3):140-6. [QxMD MEDLINE Link]. [Full Text].

13. Dolgin JG, Nix DE, Sanchez J, Watson WA. Pharmacokinetic simulation of the effect of multiple-dose activated charcoal in phenytoin poisoning--report of two pediatric cases. DICP. 1991 Jun. 25(6):646-9. [QxMD MEDLINE Link].

14. Chan BS, Sellors K, Chiew AL, Buckley NA. Use of multi-dose activated charcoal in phenytoin toxicity secondary to genetic polymorphism. Clin Toxicol (Phila). 2015 Feb. 53 (2):131-3. [QxMD MEDLINE Link].

15. Skinner CG, Chang AS, Matthews AS, Reedy SJ, Morgan BW. Randomized controlled study on the use of multiple-dose activated charcoal in patients with supratherapeutic phenytoin levels. Clin Toxicol (Phila). 2012 Sep. 50 (8):764-9. [QxMD MEDLINE Link].

16. Cumpston K, Stromberg P, Wills BK, Rose SR. Activated Charcoal Does Not Reduce Duration of Phenytoin Toxicity in Hospitalized Patients. Am J Ther. 2016 May-Jun. 23 (3):e773-7. [QxMD MEDLINE Link].

17. Ghannoum M, Troyanov S, Ayoub P, Lavergne V, Hewlett T. Successful hemodialysis in a phenytoin overdose: case report and review of the literature. Clin Nephrol. 2010 Jul. 74(1):59-64. [QxMD MEDLINE Link].

18. Sahoo JN, Gurjar M. Should we do early and frequent charcoal hemoperfusion in phenytoin toxicity?. Indian J Crit Care Med. 2016 Feb. 20 (2):123-5. [QxMD MEDLINE Link]. [Full Text].

19. De Schoenmakere G, De Waele J, Terryn W, Deweweire M, Verstraete A, Hoste E, et al. Phenytoin intoxication in critically ill patients. Am J Kidney Dis. 2005 Jan;. 45(1):189-92. [QxMD MEDLINE Link].

Charlene Miller, MD Consulting Staff, Department of Emergency Medicine, Oakwood Hospital Medical Center

Charlene Miller, MD is a member of the following medical societies: American College of Emergency Physicians

Disclosure: Nothing to disclose.

Daniel M Joyce, MD Consulting Staff, Department of Emergency Medicine, Saint Vincent's and Saint Mary's Medical Center

Daniel M Joyce, MD is a member of the following medical societies: American College of Emergency Physicians, American Medical Association

Disclosure: Nothing to disclose.

John T VanDeVoort, PharmD Regional Director of Pharmacy, Sacred Heart and St Joseph's Hospitals

John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists

Disclosure: Nothing to disclose.

Fred Harchelroad, MD, FACMT, FAAEM, FACEP Attending Physician in Emergency Medicine and Medical Toxicology, Excela Health System

Fred Harchelroad, MD, FACMT, FAAEM, FACEP is a member of the following medical societies: American College of Medical Toxicology

Disclosure: Nothing to disclose.

David Vearrier, MD, MPH Professor of Emergency Medicine, Department of Emergency Medicine, University of Mississippi Medical Center

David Vearrier, MD, MPH is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Medical Toxicology, American College of Occupational and Environmental Medicine

Disclosure: Nothing to disclose.

Lance W Kreplick, MD, FAAEM, MMM, UHM Staff Physician, Teladoc Health; President and Chief Executive Officer, QED Medical Solutions, LLC

Lance W Kreplick, MD, FAAEM, MMM, UHM is a member of the following medical societies: American Academy of Emergency Medicine, American Association for Physician Leadership

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article